
Eugit Therapeutics
Eugit Therapeutics is a YC Summer 2022 (S22) company. Based in San Carlos, CA, USA; South San Francisco, CA, USA. Team of 2.
About Eugit Therapeutics
Summary
Eugit Therapeutics develops a precision drug delivery platform that uses T cell receptors to direct therapeutics specifically to diseased tissues, replacing the blunt, systemic dosing that causes toxicity and drives clinical trial failures. The initial target is inflammatory bowel disease, where current treatments circulate broadly and damage healthy tissue. The platform, called TAGHOME, is designed to improve both the safety profile and therapeutic efficacy of existing drugs by restricting their activity to the site of inflammation.
From the Y Combinator listing
Enabling Tissue Targeting of Therapies
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Facts
- Healthcare / Healthcare -> Therapeutics
- San Carlos, CA, USA; South San Francisco, CA, USA
- 2
- Active
- Early
Founders (1)
- Nizar Batada
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works